Nicole V. Tolan

Nicole V. Tolan

Auto-generated profile, based on publicly available information

Nicole V. Tolan

Department of Pathology, Brigham and Women's Hospital 1 , Boston, MA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2021 in The Journal of Applied Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JTJonathan M Tsai
Jonathan M Tsai
NTNicole V Tolan
Nicole V Tolan
APAthena K Petrides
Athena K Petrides
SKSanjat Kanjilal
Sanjat Kanjilal
MBManfred Brigl
Manfred Brigl
SMStacy E. F. Melanson
Stacy E. F. Melanson
The COVID-19 pandemic has made a devastating impact on global health and continues to challenge healthcare infrastructure and delivery. The clinical laboratories were no exception as they are responsible for diagnostic testing that dictates many clinical, infection control, and public health decisions. Information technology and laboratory management tools are critical assets for maintaining and adapting operations in response to crises. When utilized effectively, they promote the integration between the clinical laboratory specialties (e.g., chemistry, hematology, microbiology, and molecular pathology). During the COVID-19 pandemic, our systems and processes were strained due to high testing volumes, demand for rapid turnaround times, supply chain constraints, and constantly evolving testing algorithms and result interpretations as our knowledge of the virus and of diagnostics increased over time. In this report, we describe those challenges and subsequent adaptations made by each clinical laboratory section. We hope these details help to provide potential solutions and approaches for other hospitals facing COVID-19 surges or other future pandemics.

22 December 2021 in Clinical Toxicology
Verified
Journal Article
Closed access
NTNicole V. Tolan
Nicole V. Tolan
TTTolumofe Terebo
Tolumofe Terebo
PCPeter R. Chai
Peter R. Chai
TETimothy B. Erickson
Timothy B. Erickson
BHBryan D. Hayes
Bryan D. Hayes
SMStacy E. F. Melanson
Stacy E. F. Melanson
Cannabis is widely used in the United States despite federal laws. In US states that have progressed toward legalization, there have been various reported impacts on cannabis-related emergency depa...

4 March 2022 in Clinics In Laboratory Medicine
Verified
Journal Article
Closed access
NTNicole V. Tolan
Nicole V. Tolan
GHGary L. Horowitz
Gary L. Horowitz

27 April 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
NTNicole V. Tolan
Nicole V. Tolan
ASAmy C. Sherman
Amy C. Sherman
GZGuohai Zhou
Guohai Zhou
KNKatherine G. Nabel
Katherine G. Nabel
MDMichaël Desjardins
Michaël Desjardins
STSarah E. Turbett
Sarah E. Turbett
We evaluated anti-spike antibody concentrations in healthy mRNA vaccinated individuals and compared these concentrations to values obtained from pseudotype neutralization assays targeting SARS-CoV-2 variants of concern to determine how well anti-spike antibodies correlate with neutralizing titers, which have been used as a marker of immunity from COVID-19 infection. We found high peak anti-spike concentrations in these individuals, with significantly higher levels seen in mRNA-1273 vaccine recipients.

3 April 2023 in Clinical Toxicology
Verified
Journal Article
Closed access
NTNicole V. Tolan
Nicole V. Tolan
MKMatthew D. Krasowski
Matthew D. Krasowski
PMPatrick C. Mathias
Patrick C. Mathias
JWJoesph R. Wiencek
Joesph R. Wiencek
NBNikolina Babic
Nikolina Babic
SMStacy E. F. Melanson
Stacy E. F. Melanson
Many states in the United States have progressed towards legalization of marijuana including decriminalization, medicinal and/or recreational use. We studied the impact of legalization on cannabis-...

25 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
Eric James NillesEric James Nilles
Eric James Nilles
BKBeth W Karlson
Beth W Karlson
MNMaia Norman
Maia Norman
TGTal Gilboa
Tal Gilboa
SFStephanie Fischinger
Stephanie Fischinger
LBLindsey R. Baden
Lindsey R. Baden
Background: Seroepidemiology is an important tool to characterize the epidemiology and immunobiology of SARS-CoV-2 but many immunoassays have not been externally validated raising questions about reliability of study findings. To ensure meaningful data, particularly in a low seroprevalence population, assays need to be rigorously characterized with high specificity. Methods: We evaluated two commercial (Roche Diagnostics and Epitope Diagnostics IgM/IgG) and two non-commercial (Simoa and Ragon/MGH IgG) immunoassays against 68 confirmed positive and 232 pre-pandemic negative controls. Sensitivity was stratified by time from symptom onset. The Simoa multiplex assay applied three pre-defined algorithm models to determine sample result. Results: The Roche and Ragon/MGH IgG assays each registered 1/232 false positive, the primary Simoa model registered 2/232 false positives, and the Epitope registered 2/230 and 3/230 false positives for the IgG and IgM assays respectively. Sensitivity >21 days post symptom-onset was 100% for all assays except Epitope IgM, but lower and/or with greater variability between assays for samples collected 9-14 days (67-100%) and 15-21 days (69-100%) post-symptom onset. The Simoa and Epitope IgG assays demonstrated excellent sensitivity earlier in the disease course. The Roche and Ragon/MGH assays were less sensitive during early disease, particularly among immunosuppressed individuals. Conclusions: The Epitope IgG demonstrated good sensitivity and specificity. The Roche and Ragon/MGH IgG assays registered rare false positives with lower early sensitivity. The Simoa assay primary model had excellent sensitivity and few false positives. Summary: SARS-CoV-2 immunoassays can be valuable tools for informing the global response, but many currently available assays have not been independently validated. We conducted a performance assessment of four assays including the Roche Diagnostics and Epitope Diagnostics immunoassays.